COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis?

Akande, Oluwatosin Wuraola; Igumbor, Ehimario Uche; Elimian, Kelly Osezele; Ohonsi, Cornelius Ehizokhai; Nwozor, Lilian; Oden, Okanke; Ekpenyong, Emmanuel Nsa; Ndodo, Nnaemeka; Ike, Ifeanyi F; Egede, Magdalene; +6 more...Nwachukwu, William; Onoja, Amedu M; Fofah, Jenson Gawain; Azi, Reuben Ishiaku; Ochu, Chinwe L; and Adetifa, Ifedayo M

(2022) COVID-19 vaccine effectiveness studies in Nigeria: Quo vadis? Journal of global health, 12. 03055-. ISSN 2047-2978 DOI: 10.7189/jogh.12.03055

Copy

The “lickety-split” development of COVID-19 vaccines 326 days from when the SARS-COV-2 virus was first sequenced is indeed one of the public health successes of the 21st century. Particularly because an 18-month target was initially considered reasonable, and having achieved this success, a “moonshot” goal to ensure that a vaccine is available within 100 days after the next pandemic pathogen is recognized has been set [1].